Codexis to Receive Up to $25 Million of Initial Payments, Plus Additional Milestone and Royalty Opportunities
REDWOOD CITY, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS) , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the signing of a platform technology license agreement with GlaxoSmithKline (GSK).
Under the terms of the agreement, Codexis granted GSK a license to use Codexis' proprietary CodeEvolver® protein engineering platform technology in the field of human healthcare.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.